D&D PHARMATECH
D&D Pharmatech is a operator of a holding company created to fund the development of therapeutic medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. The company's product pipeline focuses on a range of indications including neurodegenerative, metabolic and fibrotic diseases, providing the opportunity to accelerate the translation of cutting-edge research into lifesaving therapeutic products for patients.
D&D PHARMATECH
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2014-01-01
Status:
Active
Total Funding:
224.1 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Apache Mobile Non Scaleable Content Google Apps For Business Google Maps Google Maps API Sectigo SSL
Similar Organizations
FAB Pharmaceuticals
FAB Pharmaceuticals is a Health Care Company.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Pearl Care
Pearl Care is Healthcare company.
Pharmate
Pharmate is a health care company.
StanPlus
A Health And Healthcare Company.
Trinomab
Trinomab is a Healthcare company.
Current Employees Featured
Founder
Investors List
DS Asset Management
DS Asset Management investment in Series C - D&D Pharmatech
Praxis Capital Partners
Praxis Capital Partners investment in Series C - D&D Pharmatech
Korea Investment Securities
Korea Investment Securities investment in Series C - D&D Pharmatech
Kudos Venture Capital
Kudos Venture Capital investment in Series C - D&D Pharmatech
Magna Investment
Magna Investment investment in Series B - D&D Pharmatech
InterVest Co.
InterVest Co. investment in Series B - D&D Pharmatech
Octave Life Sciences
Octave Life Sciences investment in Series B - D&D Pharmatech
LB Investment
LB Investment investment in Series B - D&D Pharmatech
Smilegate Investment
Smilegate Investment investment in Series B - D&D Pharmatech
LB Investment
LB Investment investment in Series A - D&D Pharmatech
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2018-07-18 | Neuraly | D&D Pharmatech investment in Series A - Neuraly | 36 M USD |
More informations about "D&D Pharmatech"
D&D Pharmatech
D&D Pharmatech leverages industry-leading technologies in new drug development. VIEW MORE. Pipeline. A portfolio of GLP-1 peptide-based therapeutics for metabolic diseases โฆSee details»
D&D Pharmatech
D&D Pharmatech. Building a global biotech company. We dream of world. where disease doesnโt stand. in the way. ์์ ์ ํจ์ฑ์ด ํ์ธ๋ ๋์ฌ์ฑ์งํ ์น๋ฃ์ ๊ฐ๋ฐ ๊ฒฝ๊ตฌํ/์ง์ํ ๊ธฐ์ ์ด ์ ๋ชฉ๋ โฆSee details»
D&D Pharmatech - Crunchbase Investor Profile & Investments
D&D Pharmatech is a operator of a holding company created to fund the development of therapeutic medicines through disease-specific subsidiary companies founded and guided by โฆSee details»
D&D Pharmatech Co., Ltd.
Jun 3, 2023 About D&D Pharmatech D&D Pharmatech is a clinical-stage biopharmaceutical company focused on developing revolutionary medicines for patients with metabolic, fibrotic, โฆSee details»
DnD Pharmatech (South Korea) Funding: $137M
Feb 26, 2025 D&D Pharmatech is a biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided โฆSee details»
D&D Pharmatech, Metsera expand collaboration for new obesity
Mar 18, 2024 D&D Pharmatech, a Korean biotech company, said it expanded its collaboration with the U.S.-based Metsera for new treatments. This expansion includes amendments to a โฆSee details»
D&D Pharmatech - Biotech Careers
D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided โฆSee details»
D&D Pharmatech - VentureRadar
D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided โฆSee details»
D&D Pharmatech receives FDA nod for phase 2 GLP-1R โฆ
Sep 3, 2024 Additionally, D&D Pharmatech revealed that the International Progressive MS Alliance, a global nonprofit organization that supports research into progressive MS, is considering funding the trial. The company also noted โฆSee details»
BIOTECH (170) D&D Pharmatech: GLP-1R NLY01 Clinical Failure โฆ
Apr 5, 2024 D&D Pharmatech, a Korean biotech company, said it expanded its collaboration with the U.S.-based Metsera for new treatments. This expansion includes amendments to a โฆSee details»
D&D Pharmatech
In terms of research and development, D&D Pharmatech holds proprietary rights for substances and applications in its key ongoing projects, and oversees early-stage discovery research for โฆSee details»
D&D Pharmatech - Craft
D&D Pharmatech is a clinical-stage biological technology company. The company runs its global product development operations via multiple partnerships and owns subsidiaries focused on โฆSee details»
[JPM2025] D&D Pharmatech draws attention at JPM2025 โฆ
Jan 16, 2025 SAN FRANCISCO, Calif. -- By Kim Chan-hyuk/Korea Biomedical Review correspondent --D&D Pharmatech received intense attention from global pharmaceutical โฆSee details»
D&D Pharmatech - Funding, Financials, Valuation & Investors
D&D Pharmatech is registered under the ticker KOSDAQ:347850 . Their stock opened with โฉ33,000.00 in its Apr 24, 2024 IPO. D&D Pharmatech is funded by 13 investors. DS Asset โฆSee details»
D&D PharmaTech. Information about the issuer. . News and credit โฆ
D&D Pharmatech Inc. operates pharmaceutical production businesses. The Company develops and researches alzheimer disease, parkinson and other drugs. ... Operating organization โฆSee details»
Korean biopharma companies gear up for global expansion at J.P.
Jan 2, 2025 D&D Pharmatech will hold meetings with multinational pharmaceutical companies to discuss its main pipeline and platform technologies. The company is advancing clinical trials โฆSee details»
D&D Pharmatech
D&D Pharmatech is at the forefront of developing advanced peptide-based therapeutics, targeting the root causes of diseases to significantly enhance patient outcomes. Our commitment is to โฆSee details»
DD-15 - Drug Targets, Indications, Patents - Synapse - Patsnap
4 days ago Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.See details»
๋์ค๋ํ๋งํ - ddpharmatech.com
D&D Pharmatech is currently developing DD01 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and is committed to provide access to our investigational โฆSee details»
Ahead of IPO, D&D Pharmatech wins US fast track for MASH drug
Apr 4, 2024 Building D&D Pharmatech Inc. has been a rollercoaster ride, according to CEO Seulki Lee. The U.S. and Korea-based biotech is on another ascent, having scored U.S. FDA โฆSee details»